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Okayama University research: Compound-protein combination shows promise for arthritis 
treatment 
  
(Okayama, 30 May) Screening over 700 compounds reveals a steroid hormone with the 
capability to promote the repair of cartilage in joints. 
 
Damaged cartilage leads to pain and reduced joint mobility in millions of arthritis sufferers 
worldwide, yet there remains a lack of effective treatments.  Now Emilio Satoshi and Takuo 
Kaboki and colleagues at Okayama University Graduate School of Medicine, the National 
Institutes of Health in the US and Harvard School of Dental Medicine identify a steroid 
hormone that could help cartilage development - ‘chondrogenesis’ – thereby regenerating 
the damaged joint tissue.  
 
The researchers screened cultures of cartilage stem cells with over 700 compounds for 
substances associated with chondrogenesis, and identified enhancements to these 
substances in the presence of the steroid hormone fluocinolone acetonide (FA). The 
researchers then studied cultures of the stem cells that develop into bone and cartilage cells 
in cultures of FA and transforming growth factor beta 3 (TGF-β3).  Previous studies have 
reported that TGF-β3 plays an important role in chondrogenesis, but antagonistic effects on 
the development and proliferation of cartilage cells have also been observed, particularly in 
the presence of certain other bioactive proteins.   
 
In experiments in vitro the researchers found that both TGF-β3 and FA inhibit 
chondrogenesis, but when present together they upregulate both a key marker and a 
regulator for chondrocytes. Further experiments highlighted the cellular pathways for the 
enhanced activity.  
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In addition the researchers confirmed the effects of the combined compounds in 
experiments with mice. “The in vivo cartilage repair model confirmed that FA/TGF-β3 is 
uniquely able to promote cartilage repair,” report the researchers. They add that the 
combination could have potential for clinical applications based on the development of 
stem cells into cartilage cells.   
 
Background 
Chondrogenesis 
The only cells that exist in healthy cartilage are chondrocytes. Previous efforts to promote 
chondrogenesis using growth factors, gene therapy and compounds have had limited 
success as the cartilage does not readily regenerate. Harnessing the ability to develop 
cartilage cells from stem cells offers a promising approach to aiding cartilage regeneration 
but has not yet been achieved. 
 
Previous research has pointed towards transforming growth factor beta and insulin-like 
growth factors as the main contributors towards chondrogenesis. This suggests that some 
combination of these proteins would enhance differentiation of human bone marrow 
stem/progenitor cells (hBMSCs) - the stem cells that develop into bone and cartilage cells. 
However previous experiments to study the effects of different combinations of these 
proteins revealed antagonistic effects on chondrogenesis. 
 
The screening tests 
The researchers screened a Food and Drug Administration (FDA)-approved drug library 
containing 640 compounds and an orphan ligand library containing 84 compounds. They 
checked the cultures of the compounds for the presence of the promoter for a gene of a 
type of collagen that makes up the majority of the cartilage protein in joints (Col2a1 
promoter), as well as a known marker (Acan) and a known regulator of chondrocytes (Sox9). 
 
They found 86 compounds that enhance Col2a1 promoter, 8 that regulated Acan but just 
one that upregulated Sox9 as well, that is, FA. FA is a gluococorticoid, a type of hormone 
that takes its name from its steroid structure, its role in glucose metabolism, and because it 
is synthesised in the adrenal cortex and plays an important.  
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Clinical use of glucocorticoids 
Glucocorticoids are already used for clinical applications. FA is currently mainly used for 
dermal, dental and ophthalmological prescriptions and TA and DEX, which have similar 
structures, have already been used in injections for the management of joint diseases. While 
glucocorticoid injections are widely used to treat in rheumatoid arthritis and other joint 
diseases, they have been recognised as harmful to cartilage over prolonged use, possibly 
due to inhibiting effects on the development of cartilage cells from stem cells. Investigation 
of alternative glucocorticoids may decrease cartilage damage from long-term use. 
 
The researchers found that FA/TMFβ3 enhanced chondrogenesis by enhancing the activity 
of the mTORC1/AKT pathway. As AKT inhibitors have been used as a chemotherapeutic 
treatment for tumors, exploitation of these effects to treat arthritis will require caution. 
 
 
Figure caption 
Among glucocorticoids, FA/TGF-β3 is uniquely able to promote articular surface 
regeneration. Substantial cartilage repair of the knee joints in mice was observed only in the 
group transplanted with hBMSCs treated with FA/TGF-β3. Arrowheads show the borders of 
the surgical defect. The asterisk shows the regenerated superficial layer of the articular 
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cartilage only in FA/TGF-β3 group. Arrows indicate articular surface damage in the groups 
that received TA/TGF-β3-treated hBMSCs. 
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Okayama University Medical Research Updates （OU-MRU） 
Vol.1：Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells 
from blood samples for genetic testing 
Vol.2：Ensuring a cool recovery from cardiac arrest 
Vol.3：Organ regeneration research leaps forward 
Vol.4：Cardiac mechanosensitive integrator 
Vol.5：Cell injections get to the heart of congenital defects 
Vol.6：Fourth key molecule identified in bone development 
Vol.7：Anticancer virus solution provides an alternative to surgery 
Vol.8：Light-responsive dye stimulates sight in genetically blind patients 
Vol.9：Diabetes drug helps towards immunity against cancer 
Vol.10：Enzyme-inhibitors treat drug-resistant epilepsy 
 
 
 
 
 
 
 
 
 
 
 
 
 
About Okayama University 
Okayama University is one of the largest 
comprehensive universities in Japan with 
roots going back to the Medical Training 
Place sponsored by the Lord of Okayama 
and established in 1870. Now with 1,300 
faculty and 14,000 students, the University 
offers courses in specialties ranging from 
medicine and pharmacy to humanit ies 
a n d  p h y s i c a l  s c i e n c e s .  O k a y a m a 
University is located in the heart of Japan 
approximately 3 hours west of Tokyo by 
Shinkansen. 
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